CN112674908A - Bending-resistant dry biological heart valve and preparation method thereof - Google Patents
Bending-resistant dry biological heart valve and preparation method thereof Download PDFInfo
- Publication number
- CN112674908A CN112674908A CN202011501321.1A CN202011501321A CN112674908A CN 112674908 A CN112674908 A CN 112674908A CN 202011501321 A CN202011501321 A CN 202011501321A CN 112674908 A CN112674908 A CN 112674908A
- Authority
- CN
- China
- Prior art keywords
- heart valve
- sulfonyl chloride
- solution
- alkyl sulfonyl
- soaked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a preparation method of a bending-resistant dry biological heart valve, which comprises the following steps: s11, soaking the animal heart valve in a glutaraldehyde solution to obtain the animal heart valve soaked in the glutaraldehyde solution; s12, soaking the obtained animal heart valve soaked by the glutaraldehyde solution in an alkyl sulfonyl chloride solution to obtain the animal heart valve soaked by the alkyl sulfonyl chloride solution; s13, dehydrating and drying the animal heart valve soaked in the alkyl sulfonyl chloride solution through an alcohol solution to obtain the bending-resistant biological heart valve. After the technical treatment of the invention, the artificial biological valve can be preserved in a dry state, thereby avoiding the sterilization treatment and liquid preservation of aldehyde substances and effectively reducing the residual risk of the aldehyde substances.
Description
Technical Field
The invention relates to the technical field of biomedical materials, in particular to a bending-resistant dry biological heart valve and a preparation method thereof.
Background
Valvular heart disease is a common heart disease in China, and valve damage caused by rheumatic fever is the most common. With the aging of the population, senile valvular diseases, coronary heart diseases and valvular diseases caused by myocardial infarction are more and more common. According to the statistics of flow direction pathology investigation, the incidence rate of heart valvular diseases in China is 2.5% -3.2%. Wherein the incidence rate of valvular heart disease of old people over 75 years old is up to 13.3%. Valvular heart disease with mild symptoms can be treated with drugs, but in severe cases, only surgical approaches can be used to replace the valve. In the traditional surgical operation, the chest is opened, the heart is stopped, an extracorporeal circulation system is established, not all patients can tolerate the operation, and the later recovery needs a long time. And the trans-catheter aortic replacement (TAVR) is a minimally invasive operation in which a delivery system is used to implant a prosthetic heart valve into the heart by puncturing the femoral artery or other suitable blood vessels, and the postoperative recovery is fast during the operation period. The trans-catheter aortic replacement has higher improvement on the postoperative life quality of patients, and has wider market prospect.
At present, the artificial heart valve adopts pig pericardium or bovine pericardium as a main biological material, adopts glutaraldehyde solution with certain concentration for fixation and storage, and is always in a wet state in the process before replacement. Before surgery, the valve is rinsed and then placed in the desired position using a squeeze and load conveyor. Prolonged immersion in glutaraldehyde solution increases the risk of toxicity and calcification of the valve. And the valve soaked with the solution containing glutaraldehyde is eluted before the operation, so it takes a long time and there is a risk of glutaraldehyde residue.
To address the above problems, some companies have begun to develop dried valves, thereby reducing the use of glutaraldehyde. The drying method of the artificial heart valve generally adopts one or more alcohol solutions to carry out dehydration treatment, and drying is carried out at a certain temperature, the obtained valve does not need to be stored in a glutaraldehyde solution, and normal saline is used for hydration before the operation, so that the time is saved, and the residue of the glutaraldehyde is reduced. However, such a dried valve has a certain reduction in mechanical strength and durability, and the biological valve undergoes leaflet delamination, tearing, and the like during fatigue testing. The long-term bending storage enables the biological valve to have folds which are difficult to eliminate after rehydration.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a bending-resistant dry biological heart valve and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a method of making a bend-resistant dry biological heart valve, comprising:
s1, soaking an animal heart valve in a glutaraldehyde solution to obtain the animal heart valve soaked in the glutaraldehyde solution;
s2, soaking the obtained animal heart valve soaked by the glutaraldehyde solution in an alkyl sulfonyl chloride solution to obtain the animal heart valve soaked by the alkyl sulfonyl chloride solution;
s3, dehydrating and drying the animal heart valve soaked in the alkyl sulfonyl chloride solution through an alcohol solution to obtain the bending-resistant biological heart valve.
Further, the concentration of the alkyl sulfonyl chloride in the alkyl sulfonyl chloride solution is 0.1% -5%; the alkyl sulfonyl chloride is one of dodecyl sulfonyl chloride, dodecyl benzene sulfonyl chloride, pentadecyl sulfonyl chloride, hexadecyl sulfonyl chloride and octadecyl sulfonyl chloride.
Further, the alkyl sulfonyl chloride solution in step S2 further includes adding an emulsifier to the alkyl sulfonyl chloride.
Further, the emulsifier is one of alkyl glycoside, sodium dodecyl sulfate, polyethylene glycol caprylic acid, glyceryl decanoate, polyethylene glycol lauric acid glyceride, polyethylene glycol glyceryl stearate, carboxymethyl cellulose and polyoxyethylene alkyl ether; the concentration of the emulsifier is 0.01-1%.
Further, in the step S2, the animal heart valve soaked in the glutaraldehyde solution is soaked in the alkyl sulfonyl chloride solution at a temperature of 40 ℃ to 60 ℃ for 1 to 3 hours.
Further, in the step S1, the animal heart valve is soaked in the glutaraldehyde solution at the soaking temperature of 20-45 ℃ for 1 hour-7 days; the concentration of the glutaraldehyde solution is 0.1% -5%; the pH value of the glutaraldehyde solution is 7-8.
Further, the alcohol solution in step S3 is one or more of methanol, ethanol, n-propanol, isopropanol, glycerol, n-butanol, and n-pentanol; the alcohol solution dehydration and drying treatment is to adopt alcohol solution with gradient concentration for dehydration and drying.
Further, the alcohol solution with gradient concentration comprises:
i: 25% ethanol/75% glycerol;
II: 50% ethanol/50% glycerol;
III: 75% ethanol/25% glycerol.
Further, the step S3 of dehydrating and drying with alcohol solution is to soak the animal heart valve in the three solutions i, ii, and iii at 25-35 ℃ for 1-7 days, respectively, to complete dehydration and drying.
Correspondingly, a bending-resistant dry biological heart valve is also provided, and the biological heart valve is prepared based on a preparation method of the bending-resistant dry biological heart valve.
Compared with the prior art, the invention has the beneficial effects that:
1. after the technical treatment of the invention, the artificial biological valve can be preserved in a dry state, thereby avoiding the sterilization treatment and liquid preservation of aldehyde substances and effectively reducing the residual risk of the aldehyde substances;
2. the strength and toughness of the pericardium are enhanced through secondary crosslinking, and the pericardium can better resist external force and is not subjected to plastic deformation;
3. the use of the alkyl sulfonyl chloride is equivalent to a lubricating effect, so that the collagen fibers can better slide when being bent by external force, and the formation of wrinkles is reduced.
Drawings
Fig. 1 is a flow chart of a method for making a kink-resistant dry biological heart valve according to one embodiment.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention. It is to be noted that the features in the following embodiments and examples may be combined with each other without conflict.
The invention aims to overcome the defects of the prior art and provides a bending-resistant dry biological heart valve and a preparation method thereof.
Example one
The present embodiment provides a method for preparing a bending-resistant dry biological heart valve, as shown in fig. 1, including:
s11, soaking the animal heart valve in a glutaraldehyde solution to obtain the animal heart valve soaked in the glutaraldehyde solution;
s12, soaking the obtained animal heart valve soaked by the glutaraldehyde solution in an alkyl sulfonyl chloride solution to obtain the animal heart valve soaked by the alkyl sulfonyl chloride solution;
s13, dehydrating and drying the animal heart valve soaked in the alkyl sulfonyl chloride solution through an alcohol solution to obtain the bending-resistant biological heart valve.
This embodiment is for improving the resistant performance of bending after the valve is dry, still do not have the fold through long-time folding, add alkyl sulfonyl chloride after using glutaraldehyde crosslinking and handle, chlorine in the alkyl sulfonyl chloride can react with the amino in the collagen, further crosslinking for pericardium toughness and intensity reinforcing, and sulfonyl base agent can make the fibre more easily slide when receiving to bend, and difficult production fold makes the pericardium can tolerate long-time stress and not take place plastic deformation.
In step S11, the animal heart valve is soaked in the glutaraldehyde solution, so as to obtain the animal heart valve soaked in the glutaraldehyde solution.
Soaking animal heart valve in 0.1-5% glutaraldehyde solution, and crosslinking at 20-45 deg.C for 1 hr-7 days; preferably, the crosslinking time is 3 to 24 hours. Wherein the pH value of the glutaraldehyde solution is 7-8.
In step S12, the obtained animal heart valve soaked in the glutaraldehyde solution is soaked in an alkyl sulfonyl chloride solution to obtain an animal heart valve soaked in an alkyl sulfonyl chloride solution.
Adding an emulsifier with the concentration of 0.01-1% into alkyl sulfonyl chloride to obtain the alkyl sulfonyl chloride containing the emulsifier; preferably, the concentration of the emulsifier is 0.05% -0.5%; wherein the emulsifier is one of alkyl glycoside, sodium dodecyl sulfate, polyethylene glycol caprylic acid, glyceryl decanoate, polyethylene glycol lauric acid glyceride, polyethylene glycol glyceryl stearate, carboxymethyl cellulose and polyoxyethylene alkyl ether. The reason why the emulsifier is added to the alkylsulfonyl chloride in this example is that the alkylsulfonyl chloride is insoluble in water.
Dissolving the obtained alkyl sulfonyl chloride containing the emulsifier in water to obtain an alkyl sulfonyl chloride solution containing the emulsifier, soaking the animal heart valve soaked by the glutaraldehyde solution in the alkyl sulfonyl chloride solution containing the emulsifier, and soaking for 1-3 hours under an oscillating condition; preferably, the soaking time is 1.5 h; wherein the soaking temperature is 40-60 ℃; the volume ratio of the alkyl sulfonyl chloride solution to the animal heart valve is 1: 50 to 1: 100.
in this example, the concentration of alkylsulfonyl chloride in the alkylsulfonyl chloride solution is 0.1% to 5%; the alkyl sulfonyl chloride is one of dodecyl sulfonyl chloride, dodecyl benzene sulfonyl chloride, pentadecyl sulfonyl chloride, hexadecyl sulfonyl chloride and octadecyl sulfonyl chloride.
In step S13, the animal heart valve soaked in the alkyl sulfonyl chloride solution is dehydrated and dried by alcohol solution to obtain a bending-resistant biological heart valve.
In this embodiment, the alcohol solution is one or more of methanol, ethanol, n-propanol, isopropanol, glycerol, n-butanol, and n-pentanol.
Dehydrating and drying the animal heart valve soaked by the alkyl sulfonyl chloride solution by adopting an alcohol solution with gradient concentration to obtain the bending-resistant biological heart valve.
The alcohol solution with gradient concentration comprises:
i: 25% ethanol/75% glycerol;
II: 50% ethanol/50% glycerol;
III: 75% ethanol/25% glycerol.
The dehydration and drying treatment by alcohol solution is to soak the animal heart valve in three groups of solutions I, II and III respectively at 25-35 ℃ for 1-7 days to complete dehydration and drying. Preferably, the soaking time is 1-2 days. More preferably, the soaking time is 24 hours.
Compared with the prior art, the beneficial effect of this embodiment:
1. after the technical treatment of the invention, the artificial biological valve can be preserved in a dry state, thereby avoiding the sterilization treatment and liquid preservation of aldehyde substances and effectively reducing the residual risk of the aldehyde substances;
2. the strength and toughness of the pericardium are enhanced through secondary crosslinking, and the pericardium can better resist external force and is not subjected to plastic deformation;
3. the use of the alkyl sulfonyl chloride is equivalent to a lubricating effect, so that the collagen fibers can better slide when being bent by external force, and the formation of wrinkles is reduced.
Accordingly, the present embodiments also provide a bending-resistant dry biological heart valve, wherein the biological heart valve is prepared based on a bending-resistant dry biological heart valve preparation method.
Example two
The present embodiment provides a method for preparing a bending-resistant dry biological heart valve, which is different from the first embodiment in that:
taking fresh bovine pericardium, removing fat fibers on the surface, and the like.
1) Soaking the mixture for 24 hours at room temperature by using 5 percent glutaraldehyde solution, taking out the mixture and rinsing the mixture clean.
2) Preparing an alkyl sulfonyl chloride solution: the concentration of dodecyl sulfonyl chloride is 2%, the concentration of alkyl glycoside is 0.1%, after stirring into emulsion at room temperature, the pericardium is immersed, and the ratio of the pericardium to liquid is 1: 100.
3) at room temperature, the reaction mixture is respectively mixed in a reaction solution of I: 25% ethanol/75% glycerol, ii: 50% ethanol/50% glycerol, iii: soaking in 75% ethanol/25% glycerol for 24 hr respectively to complete dehydration and drying.
The product prepared in this example was subjected to a simulated folding test (after the sample was folded twice, a 10kg weight was folded for 30 days) and a tensile strength test, and the test results showed that the test had no significant wrinkles after the folding test and the tensile strength was greater than 10 MPa.
EXAMPLE III
The present embodiment provides a method for preparing a bending-resistant dry biological heart valve, which is different from the first embodiment in that:
taking fresh bovine pericardium, removing fat fibers on the surface, and the like.
1) Soaking the mixture for 24 hours at room temperature by using 5 percent glutaraldehyde solution, taking out the mixture and rinsing the mixture clean.
2) Preparing an alkyl sulfonyl chloride solution: the concentration of dodecyl sulfonyl chloride is 1%, the concentration of alkyl glycoside is 0.05%, after stirring into emulsion at room temperature, the pericardium is immersed, and the ratio of the pericardium to liquid is 1: 100.
3) at room temperature, the reaction mixture is respectively mixed in a reaction solution of I: 25% ethanol/75% glycerol, ii: 50% ethanol/50% glycerol, iii: soaking in 75% ethanol/25% glycerol for 24 hr respectively to complete dehydration and drying.
The product prepared in this example was subjected to a simulated folding test (after the sample was folded twice, a 10kg weight was folded for 30 days) and a tensile strength test, and the test results showed that the test had no significant wrinkles after the folding test and the tensile strength was greater than 10 MPa.
Example four
The present embodiment provides a method for preparing a bending-resistant dry biological heart valve, which is different from the first embodiment in that:
taking fresh bovine pericardium, removing fat fibers on the surface, and the like.
1) Soaking the mixture in 2.5% glutaraldehyde solution at room temperature for 24 hr, taking out and rinsing.
2) Preparing an alkyl sulfonyl chloride solution: the concentration of dodecyl sulfonyl chloride is 2%, the concentration of alkyl glycoside is 0.1%, after stirring into emulsion at room temperature, the pericardium is immersed, and the ratio of the pericardium to liquid is 1: 100.
3) at room temperature, the reaction mixture is respectively mixed in a reaction solution of I: 25% ethanol/75% glycerol, ii: 50% ethanol/50% glycerol, iii: soaking in 75% ethanol/25% glycerol for 24 hr respectively to complete dehydration and drying.
The product prepared in this example was subjected to a simulated folding test (after the sample was folded twice, a 10kg weight was folded for 30 days) and a tensile strength test, and the test results showed that the test had no significant wrinkles after the folding test and the tensile strength was greater than 10 MPa.
EXAMPLE five
The present embodiment provides a method for preparing a bending-resistant dry biological heart valve, which is different from the first embodiment in that:
taking fresh bovine pericardium, removing fat fibers on the surface, and the like.
1) Soaking the mixture in 2.5% glutaraldehyde solution at room temperature for 24 hr, taking out and rinsing.
2) Preparing an alkyl sulfonyl chloride solution: the concentration of dodecyl sulfonyl chloride is 1%, the concentration of alkyl glycoside is 0.05%, after stirring into emulsion at room temperature, the pericardium is immersed, and the ratio of the pericardium to liquid is 1: 100.
3) at room temperature, the reaction mixture is respectively mixed in a reaction solution of I: 25% ethanol/75% glycerol, ii: 50% ethanol/50% glycerol, iii: soaking in 75% ethanol/25% glycerol for 24 hr respectively to complete dehydration and drying.
The product prepared in this example was subjected to a simulated folding test (after the sample was folded twice, a 10kg weight was folded for 30 days) and a tensile strength test, and the test results showed that the test had no significant wrinkles after the folding test and the tensile strength was greater than 10 MPa.
The pericardium in the second to fifth embodiments is an animal heart valve, and the animal pericardium includes, but is not limited to, bovine pericardium, porcine pericardium, and the like. It should be clear to those skilled in the art that the products of the present invention have metal, polymeric materials as an aid to processing into artificial biological valves in addition to the biological tissue.
The specific embodiments described herein are merely illustrative of the spirit of the invention. Various modifications or additions may be made to the described embodiments or alternatives may be employed by those skilled in the art without departing from the spirit or ambit of the invention as defined in the appended claims.
Claims (10)
1. A method of making a bend-resistant dry biological heart valve, comprising:
s1, soaking an animal heart valve in a glutaraldehyde solution to obtain the animal heart valve soaked in the glutaraldehyde solution;
s2, soaking the obtained animal heart valve soaked by the glutaraldehyde solution in an alkyl sulfonyl chloride solution to obtain the animal heart valve soaked by the alkyl sulfonyl chloride solution;
s3, dehydrating and drying the animal heart valve soaked in the alkyl sulfonyl chloride solution through an alcohol solution to obtain the bending-resistant biological heart valve.
2. The method of claim 1, wherein the concentration of alkyl sulfonyl chloride in the alkyl sulfonyl chloride solution is between 0.1% and 5%; the alkyl sulfonyl chloride is one of dodecyl sulfonyl chloride, dodecyl benzene sulfonyl chloride, pentadecyl sulfonyl chloride, hexadecyl sulfonyl chloride and octadecyl sulfonyl chloride.
3. The method of claim 2, wherein the solution of alkyl sulfonyl chloride in step S2 further comprises adding an emulsifier to the alkyl sulfonyl chloride.
4. The method of claim 3, wherein the emulsifier is one of alkyl glycoside, sodium lauryl sulfate, polyethylene glycol caprylic acid, glyceryl decanoate, polyethylene glycol laurate, polyethylene glycol glyceryl stearate, carboxymethyl cellulose, polyoxyethylene alkyl ether; the concentration of the emulsifier is 0.01-1%.
5. The method of claim 1, wherein the animal heart valve soaked in the glutaraldehyde solution in step S2 is soaked in the alkyl sulfonyl chloride solution at a temperature of 40-60 ℃ for 1-3 h.
6. The method of claim 1, wherein the animal heart valve is immersed in the glutaraldehyde solution in step S1 at a temperature of 20-45 ℃ for 1 hour to 7 days; the concentration of the glutaraldehyde solution is 0.1% -5%; the pH value of the glutaraldehyde solution is 7-8.
7. The method of claim 1, wherein the alcohol solution in step S3 is one or more of methanol, ethanol, n-propanol, isopropanol, glycerol, n-butanol, and n-pentanol; the alcohol solution dehydration and drying treatment is to adopt alcohol solution with gradient concentration for dehydration and drying.
8. The method of claim 7, wherein the gradient alcohol solution comprises:
i: 25% ethanol/75% glycerol;
II: 50% ethanol/50% glycerol;
III: 75% ethanol/25% glycerol.
9. The method of claim 8, wherein the dehydration drying treatment with alcohol solution in step S3 comprises immersing the animal heart valve in three solutions i, ii, and iii at 25-35 ℃ for 1-7 days to complete dehydration drying.
10. A kink-resistant dried biological heart valve produced by the method of any one of claims 1-9 for producing a kink-resistant dried biological heart valve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011501321.1A CN112674908B (en) | 2020-12-18 | 2020-12-18 | Bending-resistant dry biological heart valve and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011501321.1A CN112674908B (en) | 2020-12-18 | 2020-12-18 | Bending-resistant dry biological heart valve and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112674908A true CN112674908A (en) | 2021-04-20 |
| CN112674908B CN112674908B (en) | 2022-05-10 |
Family
ID=75449086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011501321.1A Active CN112674908B (en) | 2020-12-18 | 2020-12-18 | Bending-resistant dry biological heart valve and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112674908B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115212352A (en) * | 2022-08-08 | 2022-10-21 | 科凯(南通)生命科学有限公司 | Preparation method of biological dry valve and biological dry valve |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022146A1 (en) * | 2001-07-26 | 2003-01-30 | Cunanan Crystal M. | Oxidized bioprosthetic materials |
| US20050113910A1 (en) * | 2002-01-04 | 2005-05-26 | David Paniagua | Percutaneously implantable replacement heart valve device and method of making same |
| CN101385870A (en) * | 2008-11-03 | 2009-03-18 | 中国人民解放军第四军医大学 | Method for improving de-cellular system engineering valve/blood vessel stent |
| CN109549761A (en) * | 2018-09-12 | 2019-04-02 | 沛嘉医疗科技(苏州)有限公司 | A kind of bioprosthesis valve and preparation method thereof |
-
2020
- 2020-12-18 CN CN202011501321.1A patent/CN112674908B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022146A1 (en) * | 2001-07-26 | 2003-01-30 | Cunanan Crystal M. | Oxidized bioprosthetic materials |
| US20050113910A1 (en) * | 2002-01-04 | 2005-05-26 | David Paniagua | Percutaneously implantable replacement heart valve device and method of making same |
| CN101385870A (en) * | 2008-11-03 | 2009-03-18 | 中国人民解放军第四军医大学 | Method for improving de-cellular system engineering valve/blood vessel stent |
| CN109549761A (en) * | 2018-09-12 | 2019-04-02 | 沛嘉医疗科技(苏州)有限公司 | A kind of bioprosthesis valve and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115212352A (en) * | 2022-08-08 | 2022-10-21 | 科凯(南通)生命科学有限公司 | Preparation method of biological dry valve and biological dry valve |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112674908B (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11207447B2 (en) | Method for preparing an animal decellularized tissue matrix material and a decellularized tissue matrix material prepared thereby | |
| EP3854425B1 (en) | Pre-loadable dried biological heart valve and preparation method thereof | |
| AU777652B2 (en) | Tissue regenerative composition | |
| EP2004250B1 (en) | Improvements relating to decellularisation of tissue matrices for bladder implantation | |
| Bielli et al. | Characterization of a new decellularized bovine pericardial biological mesh: Structural and mechanical properties | |
| CN108498869A (en) | Polyphenols crosslinking agent and its application in preparing anticalcium biovalve | |
| US8137411B2 (en) | Thin collagen tissue for medical device applications | |
| JP2002516702A (en) | Bioengineered vascular graft prostheses | |
| DE2453363B2 (en) | METHOD OF MANUFACTURING HETEROLOGICAL ARTERIAL TRANSPLANTS | |
| CN109172867A (en) | It is a kind of can fast rehydrating prepackage type biological cardiac valves and preparation method thereof | |
| TWI566789B (en) | Tissue repair material derived from fish skin and manufacturing method thereof | |
| JP2022519407A (en) | How to Prepare Living Tissue for Surgical Transplantation | |
| CN112674908B (en) | Bending-resistant dry biological heart valve and preparation method thereof | |
| CN110433341A (en) | A kind of tissue renovation material and preparation method thereof | |
| WO2022143700A1 (en) | Fold resistant dehydrated cross-linked biological material, preparation method therefor, and application thereof | |
| JPH04501077A (en) | Preparation method of bovine pericardium material and its uses | |
| CN109364298A (en) | A kind of preparation method of acellular dermal matrix material | |
| Kumar et al. | Effects of crosslinking treatments on the physical properties of acellular fish swim bladder | |
| WO2023231195A1 (en) | Preparation method for decellularized extracellular matrix tissue paper and use | |
| EP3393535A1 (en) | Methods for preparing dry cross-linked tissue | |
| Lan et al. | A combination of hydrogen bonding and chemical covalent crosslinking to fabricate a novel swim-bladder-derived dry heart valve material yields advantageous mechanical and biological properties | |
| CN109395164B (en) | Preparation method of dried animal extracellular matrix material | |
| CN112773936A (en) | Modified pericardium, preparation method thereof and artificial heart valve prosthesis | |
| EP2550029A1 (en) | Thin collagen tissue for medical device applications | |
| KR102559781B1 (en) | Multi-decellularized material for reinforcing biological tissue and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |